Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1259954.RAskx6Xmm6SdFvGUp1tpVbWKySxS9sVH6TpFYL60TCMjM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1259954.RAskx6Xmm6SdFvGUp1tpVbWKySxS9sVH6TpFYL60TCMjM130_assertion type Assertion NP1259954.RAskx6Xmm6SdFvGUp1tpVbWKySxS9sVH6TpFYL60TCMjM130_head.
- NP1259954.RAskx6Xmm6SdFvGUp1tpVbWKySxS9sVH6TpFYL60TCMjM130_assertion description "[Nine percent of patients with wild-type KRAS in primary tumors who received anti-EGFR treatment had mutant KRAS in metastases, while 11.3% patients with mutant KRAS primary tumors had wild-type KRAS in the metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1259954.RAskx6Xmm6SdFvGUp1tpVbWKySxS9sVH6TpFYL60TCMjM130_provenance.
- NP1259954.RAskx6Xmm6SdFvGUp1tpVbWKySxS9sVH6TpFYL60TCMjM130_assertion evidence source_evidence_literature NP1259954.RAskx6Xmm6SdFvGUp1tpVbWKySxS9sVH6TpFYL60TCMjM130_provenance.
- NP1259954.RAskx6Xmm6SdFvGUp1tpVbWKySxS9sVH6TpFYL60TCMjM130_assertion SIO_000772 25639985 NP1259954.RAskx6Xmm6SdFvGUp1tpVbWKySxS9sVH6TpFYL60TCMjM130_provenance.
- NP1259954.RAskx6Xmm6SdFvGUp1tpVbWKySxS9sVH6TpFYL60TCMjM130_assertion wasDerivedFrom befree-2016 NP1259954.RAskx6Xmm6SdFvGUp1tpVbWKySxS9sVH6TpFYL60TCMjM130_provenance.
- NP1259954.RAskx6Xmm6SdFvGUp1tpVbWKySxS9sVH6TpFYL60TCMjM130_assertion wasGeneratedBy ECO_0000203 NP1259954.RAskx6Xmm6SdFvGUp1tpVbWKySxS9sVH6TpFYL60TCMjM130_provenance.